Takeda Announces Alliance with Stanford University to Drive Therapeutic Discoveries
2017年8月15日 - 10:00PM
ビジネスワイヤ(英語)
Collaborative aims to transform novel,
innovative Stanford research into next-generation treatments for
disease
Takeda Pharmaceutical Company Limited (TSE: 4502) today
announced a collaboration with Stanford University to form the
Stanford Alliance for Innovative Medicines (Stanford AIM), which
will help transform novel Stanford research into next-generation
treatments for diseases. Through this unique collaboration, Takeda
and Stanford will identify projects on the path to therapeutic
discoveries and accelerate the process of bringing these drugs to
market to serve patients with unmet needs.
Stanford AIM will leverage the collective knowledge and
experience of Stanford and Takeda scientists in order to propel
health discoveries through therapeutic development. By encouraging
academic and industry scientists to work more closely together, the
partnership aims to expedite promising new medicines that represent
real and meaningful benefits for patients.
“Takeda’s alliance with Stanford demonstrates our commitment to
advancing medicines as quickly and efficiently as possible – from
drug discovery to development and ultimately to patients,” said
Juan Harrison, Vice President, Head of Strategic Academic
Alliances, Center for External Innovation, Takeda. “We look forward
to combining the intellectual capital of Takeda and Stanford
scientists, motivating both to come together as peers, in order to
deliver medicines that represent real and meaningful benefits for
patients.”
The partners expect to begin taking proposals from Stanford lab
teams in October, which will include objectives against which to
measure progress and success during key phases of research.
Together, Takeda and Stanford will identify the most promising
novel, innovative projects. Upon project selection, Takeda will
apply its best-in-class capabilities – including scientific and
clinical research and operations – to develop the pathway or
platform technology.
This type of collaboration advances the validation of projects
born at Stanford and improves the potential for discoveries to be
developed and licensed, while exposing Takeda researchers to the
latest biological discoveries and innovative chemical platforms
from a leading research university. The three-year term of the
collaboration will support four to eight projects running
concurrently at a given time.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as Takeda’s presence in Emerging Markets,
are currently fueling the growth of Takeda. More than 30,000 Takeda
employees are committed to improving quality of life for patients,
working with Takeda’s partners in health care in more than 70
countries. For more information, visit www.takeda.com/news.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward-looking statements include all statements other than
statements of historical fact, including plans, strategies and
expectations for the future, statements regarding the expected
timing of filings and approvals relating to the transaction, the
expected timing of the completion of the transaction, the ability
to complete the transaction or to satisfy the various closing
conditions, future revenues and profitability from or growth or any
assumptions underlying any of the foregoing. Statements made in the
future tense, and words such as “anticipate,” “expect,” “project,”
“continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,”
“potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,”
“assume,” “will,” “may,” “should,” and similar expressions are
intended to qualify as forward-looking statements. Forward-looking
statements are based on estimates and assumptions made by
management that are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Investors and
security holders are cautioned not to place undue reliance on these
forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements. Some
of these risks and uncertainties include, but are not limited to:
required regulatory approvals for the transaction may not be
obtained in a timely manner, if at all; the conditions to closing
of the transaction may not be satisfied; competitive pressures and
developments; applicable laws and regulations; the success or
failure of product development programs; actions of regulatory
authorities and the timing thereof; changes in exchange rates; and
claims or concerns regarding the safety or efficacy of marketed
products or product candidates in development.
The forward-looking statements contained in this press release
speak only as of the date of this press release, and neither
Stanford nor Takeda undertake any obligation to revise or update
any forward-looking statements to reflect new information, future
events or circumstances after the date of the forward-looking
statement. If one or more of these statements is updated or
corrected, investors and others should not conclude that additional
updates or corrections will be made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170815005014/en/
Takeda Contact:Kelly Schlemm –
USAkelly.schlemm@takeda.com+1-617-551-8865